Chen Yan, Liu Tangjuan, Wang Ke, Hou Changchun, Cai Shuangqi, Huang Yingying, Du Zhongye, Huang Hong, Kong Jinliang, Chen Yiqiang
The Institute of Respiratory Diseases, First Affiliated Hospital, Guangxi Medical University, Nanning, China.
PLoS One. 2016 Apr 29;11(4):e0153468. doi: 10.1371/journal.pone.0153468. eCollection 2016.
Biofilm formed by Staphylococcus aureus significantly enhances antibiotic resistance by inhibiting the penetration of antibiotics, resulting in an increasingly serious situation. This study aimed to assess whether baicalein can prevent Staphylococcus aureus biofilm formation and whether it may have synergistic bactericidal effects with antibiotics in vitro. To do this, we used a clinically isolated strain of Staphylococcus aureus 17546 (t037) for biofilm formation. Virulence factors were detected following treatment with baicalein, and the molecular mechanism of its antibiofilm activity was studied. Plate counting, crystal violet staining, and fluorescence microscopy revealed that 32 μg/mL and 64 μg/mL baicalein clearly inhibited 3- and 7-day biofilm formation in vitro. Moreover, colony forming unit count, confocal laser scanning microscopy, and scanning electron microscopy showed that vancomycin (VCM) and baicalein generally enhanced destruction of biofilms, while VCM alone did not. Western blotting and real-time quantitative polymerase chain reaction analyses (RTQ-PCR) confirmed that baicalein treatment reduced staphylococcal enterotoxin A (SEA) and α-hemolysin (hla) levels. Most strikingly, real-time qualitative polymerase chain reaction data demonstrated that 32 μg/mL and 64 μg/mL baicalein downregulated the quorum-sensing system regulators agrA, RNAIII, and sarA, and gene expression of ica, but 16 μg/mL baicalein had no effect. In summary, baicalein inhibited Staphylococcus aureus biofilm formation, destroyed biofilms, increased the permeability of vancomycin, reduced the production of staphylococcal enterotoxin A and α-hemolysin, and inhibited the quorum sensing system. These results support baicalein as a novel drug candidate and an effective treatment strategy for Staphylococcus aureus biofilm-associated infections.
金黄色葡萄球菌形成的生物膜通过抑制抗生素渗透显著增强耐药性,导致情况日益严重。本研究旨在评估黄芩苷是否能预防金黄色葡萄球菌生物膜形成,以及它在体外是否可能与抗生素产生协同杀菌作用。为此,我们使用临床分离的金黄色葡萄球菌菌株17546(t037)进行生物膜形成实验。在用黄芩苷处理后检测毒力因子,并研究其抗生物膜活性的分子机制。平板计数、结晶紫染色和荧光显微镜检查显示,32μg/mL和64μg/mL的黄芩苷在体外能明显抑制3天和7天生物膜的形成。此外,菌落形成单位计数、共聚焦激光扫描显微镜和扫描电子显微镜显示,万古霉素(VCM)和黄芩苷通常能增强对生物膜的破坏作用,而单独使用VCM则无此效果。蛋白质免疫印迹法和实时定量聚合酶链反应分析(RTQ-PCR)证实,黄芩苷处理可降低葡萄球菌肠毒素A(SEA)和α-溶血素(hla)水平。最引人注目的是,实时定性聚合酶链反应数据表明,32μg/mL和64μg/mL的黄芩苷可下调群体感应系统调节因子agrA、RNAIII和sarA以及ica的基因表达,但16μg/mL的黄芩苷则无作用。总之,黄芩苷抑制金黄色葡萄球菌生物膜形成,破坏生物膜,增加万古霉素的通透性,减少葡萄球菌肠毒素A和α-溶血素的产生,并抑制群体感应系统。这些结果支持黄芩苷作为一种新型候选药物以及治疗金黄色葡萄球菌生物膜相关感染的有效治疗策略。